Company Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.
It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC.
The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No.
3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp.
SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Country | United States |
| Founded | 1999 |
| IPO Date | May 2, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 29 |
| CEO | David Gonzalez Angulo M.D. |
Contact Details
Address: 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 United States | |
| Phone | 201-884-5485 |
| Website | scynexis.com |
Stock Details
| Ticker Symbol | SCYX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178253 |
| CUSIP Number | 811292200 |
| ISIN Number | US8112922005 |
| Employer ID | 56-2181648 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Gonzalez Angulo M.D. | Chief Executive Officer, President and Director |
| Scott Sukenick J.D. | Chief Legal Officer and Corporate Secretary |
| Ivor Macleod CPA, M.B.A. | Chief Financial Officer |
| Debbie Etchison | Executive Director of Communications |
| Daniella Gigante | Vice President of Human Resources and Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | 144 | Filing |
| Feb 5, 2024 | 144 | Filing |
| Jan 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 5, 2024 | 8-K | Current Report |